title: Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo.
abstract: Euphoric and mixed (dysphoric) manic symptoms have different response patterns to divalproex and lithium in acute mania treatment, but have not been studied in relationship to maintenance treatment outcomes. We examined the impact of initial euphoric or dysphoric manic symptomatology on maintenance outcome. Randomized maintenance treatment with divalproex, lithium, or placebo was provided for 372 bipolar I patients, who met improvement criteria during open phase treatment for an index manic episode. The current analysis grouped patients according to the index manic episode subtype (euphoric or dysphoric), and evaluated the impact on maintenance treatment outcome. The rate of early discontinuation due to intolerance during maintenance treatment was higher for initially dysphoric patients (N=249) than euphoric patients (N=123; 15.7 vs 7.3%, respectively; p=0.032). Both lithium (23.2%) and divalproex (17.1%) were associated with more premature discontinuations due to intolerance than placebo (4.8%; p=0.003 and 0.02, respectively) in the initially dysphoric patients. Among initially euphoric patients, treatment with lithium was associated with significantly more premature discontinuations due to intolerance compared to placebo (18.2 vs 0%; p=0.03), and divalproex was significantly (p=0.05) more effective than lithium, but not placebo in delaying time to a depressive episode. Initial euphoric mania appeared to predispose to better outcomes on indices of depression and overall function with divalproex maintenance than with either placebo or lithium. Dysphoric mania appeared to predispose patients to more side effects when treated with either divalproex or lithium during maintenance therapy.
authors.affiliation: Department of Psychiatry, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. bowden@uthscsa.edu
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bowden
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Collins
authors.forename: Susan L
authors.initials: SL
authors.lastname: McElroy
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Calabrese
authors.forename: Alan C
authors.initials: AC
authors.lastname: Swann
authors.forename: Richard H
authors.initials: RH
authors.lastname: Weisler
authors.forename: Patricia J
authors.initials: PJ
authors.lastname: Wozniak
mesh_terms: D000328:Adult; D018692:Antimanic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D004341:Drug Evaluation / Q000379:methods; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D013997:Time Factors; D014635:Valproic Acid / Q000627:therapeutic use*
chemical_list: D018692:Antimanic Agents; D014635:Valproic Acid; D008094:Lithium